Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF)

European Journal of Heart Failure

Volumn 9, Issue 12, 2007, Pages 1212-1222

  Angermann, Christiane E ^a   Gelbrich, Götz ^b   Störk, Stefan ^a   Fallgatter, Andreas ^a   Deckert, Jürgen ^a   Faller, Hermann ^a   Ertl, Georg ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Chronic heart failure; Cost effectiveness; Depression; Prognosis; Quality of life; Selective serotonin re uptake inhibition

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENETIC POLYMORPHISM; HEALTH CARE COST; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOOD; MORBIDITY; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AFFECT; CITALOPRAM; COGNITION; DEPRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MORBIDITY; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36248977101     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.10.005     Document Type: Article

References (48)

1. Barth J., Schumacher M., and Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 66 (2004) 802-813
2. Konstam V., Moser D.K., and De Jong M.J. Depression and anxiety in heart failure. J Card Fail 11 (2005) 455-463
3. Rutledge T., Reis V.A., Linke S.E., Greenberg B.H., and Mills P.J. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 48 (2006) 1527-1537
4. van Melle J.P., de Jonge P., Spijkerman T.A., Tijssen J.G., Ormel J., van Veldhuisen D.J., et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 66 (2004) 814-822
5. Parissis J.T., Fountoulaki K., Paraskevaidis I., and Kremastinos D. Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches. Expert Opin Investig Drugs 14 (2005) 567-577
6. van Melle J.P., de Jonge P., Ormel J., Crijns H.J., van Veldhuisen D.J., Honig A., et al. Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J 26 (2005) 2650-2656
7. Jiang W., Alexander J., Christopher E., Kuchibhatla M., Gaulden L.H., Cuffe M.S., et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 161 (2001) 1849-1856
8. Jiang W., Kuchibhatla M., Clary G.L., Cuffe M.S., Christopher E.J., Alexander J.D., et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 154 (2007) 102-108
9. Sherwood A., Blumenthal J.A., Trivedi R., Johnson K.S., O'Connor C.M., Adams Jr. K.F., et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 167 (2007) 367-373
10. Sullivan M., Simon G., Spertus J., and Russo J. Depression-related costs in heart failure care. Arch Intern Med 162 (2002) 1860-1866
11. Hu K., Gaudron P., Bahner U., Palkovits M., and Ertl G. Changes of atrial natriuretic peptide in brain areas of rats with chronic myocardial infarction. Am J Physiol 270 (1996) H312-H316
12. Hu K., Bahner U., Gaudron P., Palkovits M., Ring M., Fehle A., et al. Chronic effects of ACE-inhibition (quinapril) and angiotensin-II-type-1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction. Basic Res Cardiol 96 (2001) 258-266
13. Ertl G., Hu K., Gaudron P., Palkovits M., and Bahner U. Remodeling of the brain post myocardial infarction: focus on central ANF. Basic Res Cardiol 92 (1997) 82-84
14. Herrmann-Lingen C., Binder L., Klinge M., Sander J., Schenker W., Beyermann B., et al. High plasma levels of N-terminal pro-atrial natriuretic peptide associated with low anxiety in severe heart failure. Psychosom Med 65 (2003) 517-522
15. Hughes J.W., Watkins L., Blumenthal J.A., Kuhn C., and Sherwood A. Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J Psychosom Res 57 (2004) 353-358
16. Carney R.M., Freedland K.E., and Veith R.C. Depression, the autonomic nervous system, and coronary heart disease. Psychosom Med 67 Suppl 1 (2005) S29-S33
17. Rozanski A., Blumenthal J.A., Davidson K.W., Saab P.G., and Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol 45 (2005) 637-651
18. Musselman D.L., Tomer A., Manatunga A.K., Knight B.T., Porter M.R., Kasey S., et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 153 (1996) 1313-1317
19. Bruce E.C., and Musselman D.L. Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med 67 Suppl 1 (2005) S34-S36
20. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
21. Capuron L., Ravaud A., Miller A.H., and Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18 (2004) 205-213
22. Kop W.J., and Gottdiener J.S. The role of immune system parameters in the relationship between depression and coronary artery disease. Psychosom Med 67 Suppl 1 (2005) S37-S41
23. Glassman A.H., O'Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger Jr. J.T., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. Jama 288 (2002) 701-709
24. Berkman L.F., Blumenthal J., Burg M., Carney R.M., Catellier D., Cowan M.J., et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. Jama 289 (2003) 3106-3116
25. Taylor C.B., Youngblood M.E., Catellier D., Veith R.C., Carney R.M.., Burg M.M., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62 (2005) 792-798
26. Frasure-Smith N., Koszycki D., Swenson J.R., Baker B., van Zyl L.T., Laliberte M.A., et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosom Med 68 (2006) 87-93
27. van Melle J.P., de Jonge P., Honig A., Schene A.H., Kuyper A.M., Crijns H.J., et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 190 (2007) 460-466
28. de Jonge P., Honig A., van Melle J.P., Schene A.H., Kuyper A.M., Tulner D., et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 164 (2007) 1371-1378
29. Lesperance F., Frasure-Smith N., Koszycki D., Laliberte M.A., van Zyl L.T., Baker B., et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. Jama 297 (2007) 367-379
30. Juurlink D.N., Mamdani M.M., Kopp A., and Redelmeier D.A. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163 (2006) 813-821
31. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders. New York, NY, Biometrics.: Research Department, New York State Psychiatric Institute (1996)
32. Löwe B., Kroenke K., Herzog W., and Grafe K. Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord 81 (2004) 61-66
33. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
34. Svanborg P., and Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord 64 (2001) 203-216
35. McCaffery J.M., Frasure-Smith N., Dube M.P., Theroux P., Rouleau G.A., Duan Q., et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 68 (2006) 187-200
36. Löwe B., Kroenke K., and Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res 58 (2005) 163-171
37. Strauss D., and Shavelle R. An extended Kaplan-Meier estimator and its applications. Stat Med 17 (1998) 971-982
38. Vogels R.L., Scheltens P., Schroeder-Tanka J.M., and Weinstein H.C. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail (2006)
39. Trojano L., Antonelli Incalzi R., Acanfora D., Picone C., Mecocci P., and Rengo F. Cognitive impairment: a key feature of congestive heart failure in the elderly. J Neurol 250 (2003) 1456-1463
40. Kennedy S.H., Andersen H.F., and Lam R.W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31 (2006) 122-131
41. Serebruany V.L., Glassman A.H., Malinin A.I., Nemeroff C.B., Musselman D.L., van Zyl L.T., et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108 (2003) 939-944
42. Ziegelstein R.C., Meuchel J., Kim T.J., Latif M., Alvarez W., Dasgupta N., et al. Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 120 (2007) 525-530
43. Burke W.J., Gergel I., and Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63 (2002) 331-336
44. Faller H., Steinbüchel T., Schowalter M., Spertus J.A., Störk S., and Angermann C.E. The Kansas City Cardiomyopathy Questionnaire (KCCQ) - a new disease-specific quality of life measure for patients with chronic heart failure. Psychother Psychosom Med Psychol 55 (2005) 200-208
45. Bagby R.M., Ryder A.G., Schuller D.R., and Marshall M.B. The Hamilton Depression Rating Scale: has the gold standard become a lead weight?. Am J Psychiatry 161 (2004) 2163-2177
46. Löwe B., Schenkel I., Carney-Doebbeling C., and Gobel C. Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment. Psychosomatics 47 (2006) 62-67
47. Spitzer R.L., Kroenke K., Williams J.B.W., and Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166 (2006) 1092-1097
48. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16 (1990) 199-208